JP2011515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515490A5
JP2011515490A5 JP2011502032A JP2011502032A JP2011515490A5 JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5 JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5
Authority
JP
Japan
Prior art keywords
vaccine
cldc
adjuvanted
fish
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011502032A
Other languages
English (en)
Japanese (ja)
Other versions
JP5759890B2 (ja
JP2011515490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038307 external-priority patent/WO2009120811A1/en
Publication of JP2011515490A publication Critical patent/JP2011515490A/ja
Publication of JP2011515490A5 publication Critical patent/JP2011515490A5/ja
Application granted granted Critical
Publication of JP5759890B2 publication Critical patent/JP5759890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011502032A 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強 Expired - Fee Related JP5759890B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3938108P 2008-03-25 2008-03-25
US61/039,381 2008-03-25
PCT/US2009/038307 WO2009120811A1 (en) 2008-03-25 2009-03-25 Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)

Publications (3)

Publication Number Publication Date
JP2011515490A JP2011515490A (ja) 2011-05-19
JP2011515490A5 true JP2011515490A5 (https=) 2012-05-17
JP5759890B2 JP5759890B2 (ja) 2015-08-05

Family

ID=40791017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502032A Expired - Fee Related JP5759890B2 (ja) 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強

Country Status (6)

Country Link
US (1) US8945590B2 (https=)
EP (1) EP2257306B1 (https=)
JP (1) JP5759890B2 (https=)
BR (1) BRPI0910036B8 (https=)
CA (1) CA2719614C (https=)
WO (1) WO2009120811A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257306B1 (en) 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
WO2010130374A1 (en) * 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
BR112013016231B1 (pt) * 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
KR20160122849A (ko) 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3328423B1 (en) * 2015-07-31 2021-05-26 Bayer Animal Health GmbH Enhanced immune response in fish
SG10202000891UA (en) 2015-07-31 2020-03-30 Bayer Animal Health Gmbh Enhanced immune response in porcine species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10918709B2 (en) * 2016-10-31 2021-02-16 Eyegene Inc. Immune modulator and vaccine composition containing the same
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US6121247A (en) 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
JP2002509545A (ja) * 1997-07-08 2002-03-26 カイロン コーポレイション Dnaワクチンを伴うサブミクロン水中油型エマルジョンの使用
JP4663113B2 (ja) 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20090208781A1 (en) * 2008-02-19 2009-08-20 Skinner George A Method for operating a fuel cell system
US20110111017A1 (en) 2008-02-24 2011-05-12 Government Of The United States Of America,As Rep. By The Secretary,Dept. Of Health And Human Servic Use of immunogenic compositions for the treatment or prevention of pathogen infections
EP2257306B1 (en) 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
US20100137235A1 (en) 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species

Similar Documents

Publication Publication Date Title
JP2011515490A5 (https=)
EP2257306B1 (en) Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2720717B1 (en) Vaccine adjuvant composition comprising inulin particles
RU2020117033A (ru) Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение
EP2214705B1 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
JP2009539965A5 (https=)
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
JP2009511084A5 (https=)
JP2016506416A5 (https=)
JP2004527264A5 (https=)
RU2008119501A (ru) Функциональные вирусоподоюные частицы гриппа (vlps)
Lee et al. Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
JP2010520284A5 (https=)
JP2013522231A5 (https=)
JP2019510064A5 (https=)
JP2009511080A5 (https=)
JP7618632B2 (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
JP2016520077A5 (https=)
RU2018103757A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
CN115698295A (zh) 一种疫苗试剂和接种方法
US20130039973A1 (en) Viral Immunogenic Compositions
ES2615120T3 (es) Adyuvantes peptídicos
KR20210027168A (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом